#EULAR2025 Abstr#POS0301 Real World Multicentre study in Italy reported higher proportion of CRR at 6-mth & Lower GC in people with #lupus nephritis (~96% Class III, IV or Mixed with V) treated with Belimumab+SOC vs matched cohort on SOC. Predicted by early BEL use @RheumNow https://t.co/D6e2qo9NRL

• https://x.com/Yuz6Yusof/status/1933835385957675308/photo/1

✅Exciting results from POETYK PsA-1: -Deucravacitinib (TYK2i) in PsA -ACR 20 was achieved in significantly more patients treated with deucravacitinib vs placebo at W16 (54.2% vs 34.1%; P < 0.0001), with similar results for ACR 50 and ACR 70 -Also met 2dary endpoints. -Post hoc https://t.co/S4DhovMCma

• https://x.com/AdelaCastro222/status/1933836201460445603/photo/1
• https://x.com/AdelaCastro222/status/1933836201460445603/photo/1
• https://x.com/AdelaCastro222/status/1933836201460445603/photo/1

Hidradenitis suppurativa is newer to us in rheumatology, but it seems like inflamm arthritis is a problem - at least to a similar extent as in psoriasis. Time for us to look for it & to see what therapies like IL-17 inhibitors do for this arthritis #EULAR2025 POS1237 @RheumNow https://t.co/b5EQdDEAhq

• https://x.com/drdavidliew/status/1933837278289211854/photo/1

Social disparities in rheumatology @RheumNow #EULAR2025 ~70% of outcomes are determined by Social determinants of health Modifiable factors ? Maybe? https://t.co/UfC2nQ5Azy

• https://x.com/bella_mehta/status/1933838190474916129/photo/1

@RheumNow Achieving health equity is the goal 1.4% of GDP is lost in health inequity in EU https://t.co/50M4SfuxvX

• https://x.com/bella_mehta/status/1933839187771531734/photo/1

How much of the health outcomes are related to social determinants? 🔺️Up to 75%! Disaster Medicine Session Social disparities and impact on outcomes Dr Kate Webb #EULAR2025 @RheumNow https://t.co/0Ahbf79Nbx

• https://x.com/Nellziade/status/1933839334068666750/photo/1

#EULAR2025 Abstr#LB0007 Two’s Company, Three’s a Crowd! In 5 #SLE pts treated with CC312, a novel CD19/CD3/CD28 tri-specific ab in dose escalation showed rapid & B-cell depletion & all achieved SRI-4. No =>G2 CRS or ICANS. USP: off-the-shelf & overcome T-cell exhaustion @RheumNow https://t.co/6DZRj09JEQ

• https://x.com/Yuz6Yusof/status/1933839342335873433/photo/1

Low disease activity more difficult to achieve in vulnerable populations. All rheumatic diseases - #RA #PsA #AS initiating DMARDs takes longer in these population #EULAR2025 @RheumNow https://t.co/voIivshKRt

• https://x.com/bella_mehta/status/1933839837376766180/photo/1

What do we know about disparities in #SLE - worse in women - worse in non white populations - have lower quality of care in vulnerable populations - have worse outcomes in vulnerable populations #EULAR2025 @rheumnow Diagnosis itself is difficult in communities with poor access https://t.co/pcUaJ0eK65

• https://x.com/bella_mehta/status/1933840515411198315/photo/1

#Lupus is one of the biggest social discriminators 🔺️Higher prevalence in Women 🔺️Higher prevalence in Non-Whites 🔺️More catastrophic manifestations in low socioeconomic groups Disaster Medicine Session Social disparities and impact on outcomes #EULAR2025 @RheumNow https://t.co/mewR9NzXHt

• https://x.com/Nellziade/status/1933840890944012624/photo/1

Dual pandemic in Africa. Increasing lifestyle diseases and obesity, along with infections and malnutrition. These may be reflected in rheumatic diseases too (if they could be studied in detail) #EULAR2025 @RheumNow https://t.co/6ulMRxX8az

• https://x.com/bella_mehta/status/1933841496907645006/photo/1
• https://x.com/bella_mehta/status/1933841496907645006/photo/1

Targets for OA pain pharmacotherapies some by the wayside: - NGF - TrkA but some very much in play and exciting: - neurotrophin-3 - TRPV1 - Nav1.7, 1.8 Fiona Watt #EULAR2025 @RheumNow https://t.co/DXDKNnVRRo

• https://x.com/drdavidliew/status/1933842947922936060/photo/1

In the APEX Phase 3b RCT (N=1020), guselkumab (IL-23p19 inhibitor) significantly reduced radiographic progression (ΔvdH-S 0.55 & 0.54 vs 1.35 PBO; p≤0.002) and improved ACR20 (67–68% vs 47%) at W24 in biologic-naïve PsA. Safety consistent with prior data. Abstract LB0010 https://t.co/mFDsBsCg6m

• https://x.com/synovialjoints/status/1933843347979800810/photo/1

Migrant health literacy challenges - Individual interviews with participants with rheumatic diseases (interpreters used) multiple aspects - Individual, Providers and system level Navigating health care systems #EULAR2025 @RheumNow https://t.co/cWQ6jP8RZe

• https://x.com/bella_mehta/status/1933845338554794336/photo/1

RCT in axSpA (N=200): Digital therapeutic Axia added to stable treatment led to significant improvements in BASDAI (–1.66), BASFI (–1.12), ASQoL (–2.51), with ASAS20/40 responses of 51%/23% vs 9%/3% for usual care. Supports role of DTx in axSpA care. Abstract LB0002 @RheumNow https://t.co/oF6bjIwNIY

• https://x.com/synovialjoints/status/1933846906548928914/photo/1
• https://x.com/synovialjoints/status/1933846906548928914/photo/1